億通科技(300211.SZ):子公司鯨魚科技註冊資本擬增至5000萬元
格隆匯 3 月 9日丨億通科技(300211.SZ)公佈,公司全資子公司合肥鯨魚科技有限公司(“鯨魚科技”)主要從事集成電路、芯片、電子產品的開發、銷售;計算機軟件及系統方案開發、銷售;應用軟件服務;基礎軟件服務;數據處理、技術開發、技術服務、技術諮詢、技術轉讓、技術推廣業務。註冊資本為人民幣50萬元,鯨魚科技認繳出資額為人民幣50萬元,持股比例為100%。
為進一步增強鯨魚科技的業務能力和資金實力,公司擬使用自有資金向其增加人民幣4950萬元的註冊資本,此次增資完成後,鯨魚科技的註冊資本將由人民幣50萬元增至人民幣5000萬元,公司仍持有100%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.